Skip to content
RecruitingPhase 1

Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants

NCT07494214 · MDPS · University Hospital, Basel, Switzerland

Recruiting
Status
Accepting participants
Phase 1
Phase
20
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

This study investigates whether MDMA may have a pain-reducing effect. The effect of MDMA is compared with a placebo (a substance with no active effect). In the study, moderate pain will be artificially created in healthy participants using repeated small electrical pulses applied under the skin. At the same time, participants will take MDMA or a placebo by mouth. This allows researchers to compare how MDMA affects the artificially created pain. A total of 20 healthy volunteers will take part in this study.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • NRS

    Measured over Periprocedural

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 75 Years
Ages
All
Sex
Accepted
Healthy volunteers
Inclusion Criteria: 1. Age between 18 and 75 years old 2. Sufficient understanding of the German language 3. Understanding of procedures and risks associated with the study 4. Willing to adhere to the protocol and signing of the consent form 5. Willing to refrain from the consumption of illicit psychoactive substances during the study 6. Willing not to operate heavy machinery for 48 hours after the study session. 7. Willing to use effective birth control throughout study participation 8. Body mass index between 18-34.9 kg/m2 Exclusion Criteria: 1. Relevant chronic or acute medical condition 2. Any implanted medical devices (e.g., pacemakers, neurostimulators, or metal prostheses) 3. Current or previous major psychiatric disorder (e.g. bipolar disorder, schizophrenia), current depression or anxiety disorder. 4. Psychotic disorder or bipolar disorder in first-degree relatives 5. Hypertension (SBP\>140/90 mmHg) or hypotension (SBP\<85 mmHg) 6. Lifetime use of MDMA on more than 20 occasions or any use within the previous two months 7. Pregnancy or current breastfeeding 8. Participation in another clinical trial (currently or within the last 30 days) 9. Use of medication that may interfere with the effects of the study medication 10. Tobacco smoking (\>10 cigarettes/day) 11. Consumption of alcoholic beverages (\>15 drinks/week)

Where

1 study site

FacilityCityRegionCountry
Clinical Pharmacology & Toxicology, University Hospital BaselBaselSwitzerland

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07494214 on ClinicalTrials.gov →

Last updated in the registry 2026-03-27. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits